Canada Life
KLRS

Canada Life’s Kalaris Therapeutics KLRS Stock Holding History

Canada Life’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-86
Closed -$4K – 2222
2023
Q3 		$4K Hold
86
– – ﹤0.01% 2229
2023
Q2 		$7K Hold
86
– – ﹤0.01% 2249
2023
Q1 		$8K Hold
86
– – ﹤0.01% 2303
2022
Q4 		$10K Hold
86
– – ﹤0.01% 2327
2022
Q3 		$16K Hold
86
– – ﹤0.01% 2291
2022
Q2 		$8K Hold
86
– – ﹤0.01% 2389
2022
Q1 		$14K Hold
86
– – ﹤0.01% 2404
2021
Q4 		$25K Hold
86
– – ﹤0.01% 2336
2021
Q3 		$50K Hold
86
– – ﹤0.01% 2237
2021
Q2 		$39K Buy
86
+46
+115% +$23.8K ﹤0.01% 2339
2021
Q1 		$21K Hold
40
– – ﹤0.01% 2501
2020
Q4 		$35K Buy
+40
New +$30.8K ﹤0.01% 2401

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Canada Life's KLRS Position: Q4 2023 in Review

Canada Life sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 86 shares — an estimated $4K sold.

Canada Life first reported a position in KLRS in Q4 2020 and held it in 12 quarters. The position peaked at $50K in Q3 2021. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • Canada Life reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Canada Life sold 86 Kalaris Therapeutics shares in Q4 2023, an estimated $4K.
  • Canada Life first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 12 quarters.
  • Canada Life's Kalaris Therapeutics position peaked at $50K in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on Canada Life's 13F filing for Q4 2023, filed 13 Feb 2024.